Yahoo Finance • last month
SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (N... Full story
Yahoo Finance • 4 months ago
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading View Comments... Full story
Yahoo Finance • 5 months ago
Investing.com - H.C. Wainwright raised its price target on LENZ Therapeutics Inc (NASDAQ:LENZ) to $56.00 from $48.00 on Friday, while maintaining a Buy rating on the stock. The company, currently trading at $39.85 with a market capitalizat... Full story
Yahoo Finance • 6 months ago
* LENZ Therapeutics press release [https://seekingalpha.com/pr/20182617-lenz-therapeutics-reports-second-quarter-2025-financial-results-and-recent-corporate] (NASDAQ:LENZ [https://seekingalpha.com/symbol/LENZ]): Q2 GAAP EPS of -$0.53 bea... Full story
Yahoo Finance • 6 months ago
LENZ Therapeutics (NASDAQ:LENZ [https://seekingalpha.com/symbol/LENZ]) said Monday that CORXEL Pharmaceuticals has submitted the new drug application for LNZ100 to the Center for Drug Evaluation of the National Medical Products Administrat... Full story
Yahoo Finance • 6 months ago
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Meta Platforms Inc (Symbol: META), where a total volume of 348,474 contracts has been traded thus far today, a contract v... Full story
Yahoo Finance • 6 months ago
Investing.com - Lenz Therapeutics Inc (NASDAQ:LENZ) stock gained after William Blair reiterated its Outperform rating on the presbyopia treatment developer. The stock has shown strong momentum, rising nearly 11% in the past week, with anal... Full story
Yahoo Finance • 7 months ago
Versant Venture Capital entities reported selling shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ), for a total of $10.1 million. The sales occurred at prices ranging from $29.95 to $30.35, near the current trading price of $29.94. The stoc... Full story